Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 10/20 | 0.69 |
| ▸ | TGM1 | P22735 | 9/20 | 0.69 |
| ▸ | F13A1 | P00488 | 8/20 | 0.69 |
| ▸ | GAA | P10253 | 4/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971768 | 1.00 | TGM2 (0.69) | TGM2TGM1F13A1GAAPKM | |
| SCHEMBL3973675 | 0.94 | TGM2 (0.63) | TGM2TGM1F13A1GAAPKM | |
| SCHEMBL8394062 | 0.93 | TGM2 (0.65) | TGM2TGM1F13A1GAAPKM | |
| SCHEMBL3975724 | 0.92 | GAA (0.62) | TGM2TGM1F13A1GAAPKM | |
| SCHEMBL10064223 | 0.91 | TGM2 (0.70) | TGM2TGM1F13A1GAAKMT2A | |
| SCHEMBL1872113 | 0.88 | TGM2 (0.67) | TGM2TGM1F13A1PKMKMT2A | |
| SCHEMBL26104923 | 0.88 | TGM2 (0.67) | TGM2TGM1F13A1PKMKMT2A | |
| SCHEMBL5253097 | 0.88 | POLB (0.71) | TGM2TGM1F13A1GAAPKM | |
| SCHEMBL4235140 | 0.88 | TGM2 (0.67) | TGM2TGM1F13A1PKMKMT2A | |
| SCHEMBL12061638 | 0.87 | TGM2 (0.63) | TGM2TGM1F13A1GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | TGM2 1416/4885TGM1 1350/4885F13A1 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.